Vitamin C Affects the Expression of Hepcidin and Erythropoietin Receptor in HepG2 Cells

被引:29
作者
Chiu, Ping-Fang [1 ,2 ]
Ko, Shun-Yao [3 ]
Chang, Chia-Chu [1 ,2 ]
机构
[1] Changhua Christian Hosp, Dept Internal Med, Div Nephrol, Changhua 500, Taiwan
[2] Chung Shan Med Univ, Sch Med, Taichung, Taiwan
[3] Chang Jung Christian Univ, Inst Med Sci, Coll Hlth Sci, Tainan, Taiwan
关键词
INTRAVENOUS ASCORBIC-ACID; HEMODIALYSIS-PATIENTS; HYPORESPONSIVE ANEMIA; IRON;
D O I
10.1053/j.jrn.2011.09.007
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Backgrounds: Hepcidin modulates the de novo absorption of iron from the duodenum and the recycling of iron released from the reticuloendothelial system. In patients with chronic renal failure, administration of higher doses of erythropoietin (EPO) or vitamin C (Vit C) can correct the functional iron deficiency. While EPO-regulated hepcidin expression within hepatocytes has been recently identified, the relation between vitamin C with hepcidin expression is still uncertain. Methods: Hepcidin-producing HepG2 cells (a human liver carcinoma cell line) were cultured with 50- to 100-mu g/mL vitamin C or 0.25- to 1.0-U/mL EPO for 6 hours. Reverse transcription polymerase chain reaction was performed for quantitative measurements of hepcidin, EPO, and EPO receptor (EPOR) expression. Results: EPO and vitamin C inhibited hepcidin expression within HepG2 cells; the EPO effect was dose dependent. EPO downregulated EPOR and vitamin C and upregulated EPOR. However, vitamin C had little effect on the expression of EPO. Conclusions: EPO is capable of downregulating EPOR when it acts early. Vitamin C directly inhibits hepcidin expression within HepG2 cells. Moreover, by enhancing EPOR production, vitamin C may correct the downregulating EPOR from EPO, which has additional effect with EPO in treating anemia. (C) 2012 by the National Kidney Foundation, Inc. All rights reserved.
引用
收藏
页码:373 / 376
页数:4
相关论文
共 17 条
[1]   Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease [J].
Ashby, Damien R. ;
Gale, Daniel P. ;
Busbridge, Mark ;
Murphy, Kevin G. ;
Duncan, Neill D. ;
Cairns, Tom D. ;
Taube, David H. ;
Bloom, Stephen R. ;
Tam, Frederick W. K. ;
Chapman, Richard S. ;
Maxwell, Patrick H. ;
Choi, Peter .
KIDNEY INTERNATIONAL, 2009, 75 (09) :976-981
[2]   Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia [J].
Attallah, N ;
Osman-Malik, Y ;
Frinak, S ;
Besarab, A .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2006, 47 (04) :644-654
[3]   Parenteral ascorbic acid in haemodialysis patients [J].
Biesalski, Hans K. .
CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2008, 11 (06) :741-746
[4]   Iron Imports. I. Intestinal iron absorption and its regulation [J].
Frazer, DM ;
Anderson, GJ .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2005, 289 (04) :G631-G635
[5]   Molecular control of iron transport [J].
Ganz, Tomas .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (02) :394-400
[6]   Liver iron transport [J].
Graham, Ross M. ;
Chua, Anita C. G. ;
Herbison, Carly E. ;
Olynyk, John K. ;
Trinder, Debbie .
WORLD JOURNAL OF GASTROENTEROLOGY, 2007, 13 (35) :4725-4736
[7]   Iron regulation [J].
Himmelfarb, Jonathan .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (02) :379-381
[8]   Expression of hepcidin mRNA is uniformly suppressed in hepatocellular carcinoma [J].
Kijima, Hiroaki ;
Sawada, Tokihiko ;
Tomosugi, Naohisa ;
Kubota, Keiichi .
BMC CANCER, 2008, 8 (1)
[9]  
Macdougall C., 2007, Medicine, V35, P457
[10]   Hepcidin in anemia and inflammation in chronic kidney disease [J].
Malyszko, Jolanta ;
Mysliwiec, Michal .
KIDNEY & BLOOD PRESSURE RESEARCH, 2007, 30 (01) :15-30